E Point Perfect – Interesting and beneficial content
Law \ Legal

Celltrion Files IND with FDA for Adalimumab Biosimilar


As reported by Pulse and DailyPharm Korea, Celltrion recently filed an Investigational New Drug (IND) application with the FDA for a global Phase 3 clinical trial aimed at demonstrating its biosimilar’s (YUFLYMA) interchangeability with HUMIRA (adalimumab).  The trial will evaluate the pharmacokinetics, efficacy, and safety of YUFLYMA in 366 patients with plaque psoriasis.  Celltrion submitted its application to the FDA for approval of YUFLYMA in November 2020, and plans to launch YUFLYMA in the United States in 2023.

The post Celltrion Files IND with FDA for Adalimumab Biosimilar appeared first on Big Molecule Watch.


Source link

Related posts

Why It’s Important to Cultivate Your Alumni Network

The Briefing by the IP Law Blog – Titania v. She-Hulk: Trademark Infringement in the Marvel Universe

Its Time for the PTAB to Stop Playing Good Cop

Happy New Year! – Looking Back on 25 Years of Professional Websites – Part 2

[Podcast]: The New York City Pay Transparency Law Takes Effect

Maximizing recovery for combined wind and flood damages in hurricane claims